Sixty percent of liver cancers are preventable by controlling risk factors including hepatitis B and C, alcohol consumption, ...

Baxdrostat is a highly selective, second-generation, nonimidazole aldosterone synthase inhibitor; 100 times less baxdrostat ...

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

Shares of AstraZeneca were trading at $72.66 as of July 25. Over the last 52-week period, shares are down 7.46%. Given that these returns are generally negative, long-term shareholders are likely ...

The latest investor updates on stocks that are trending on Monday.

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited ...

At this year's American Society of Clinical Oncology’s Annual Meeting, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial evaluating first-line treatment in patients ...

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

During Brazil's COVID-19 vaccination campaign, when several brands of vaccines were available and the Chinese vaccine was the ...